Inhibitor Therapeutics Reports Q1 2026 Financial Results with Increased Net Loss

Inhibitor Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $686,425, compared to a loss of $632,846 in the same period of 2025. The company did not generate any revenue during this quarter, maintaining a trend from the previous year. Total expenses for the quarter were $695,632, which included $340,562 in research and development costs and $355,070 in general and administrative expenses. The increase in research and development expenses is attributed to fees associated with services provided by Frameshift Management, Inc., which supports the company's development program targeting basal cell carcinoma.

The company's financial position showed a significant decline in cash and cash equivalents, which decreased to $1,290,978 as of March 31, 2026, down from $2,375,493 at the end of 2025. Total current assets also fell to $1,375,953, while total liabilities decreased to $3,411,700 from $3,803,219. The stockholders' deficit widened to $1,978,337, compared to $1,291,912 at the end of the previous fiscal year, primarily due to the accumulated deficit increasing from $55,419,594 to $56,106,019.

In terms of strategic developments, Inhibitor Therapeutics has been actively pursuing opportunities to enhance its product pipeline. The company entered into a securities purchase agreement on February 19, 2026, to raise $3 million through the sale of common stock and warrants. However, as of March 30, 2026, the company initiated litigation against the institutional investor for failing to fulfill its obligations under the agreement. This situation raises concerns about the company's liquidity, as it projects insufficient cash flow to sustain operations for the next year without additional financing.

Operationally, Inhibitor Therapeutics continues to focus on the development of therapies for basal cell carcinoma using itraconazole, a drug already approved for treating fungal infections. The company has also engaged Avior Bio, Inc. for the development of a novel formulation of itraconazole and has established a master services agreement with Frameshift Management to support regulatory submissions. The company’s employee headcount remains stable, with 172,573,545 shares of common stock issued and outstanding as of March 31, 2026.

Looking ahead, Inhibitor Therapeutics acknowledges the substantial doubt about its ability to continue as a going concern due to ongoing losses and negative cash flows. The company is evaluating various financing strategies, including potential public or private sales of equity or debt securities, to address its liquidity challenges. Management remains optimistic that, if the proceeds from the securities purchase agreement are received, it will help mitigate some of the risks associated with its financial position. However, the company cautions that there are no guarantees regarding the successful execution of these plans.